Genedata Expressionist 11.0 released at ASMS 2017
Latest version of market-leading enterprise software for mass spectrometry-based biopharmaceutical characterization features efficient implementations of multi-attribute methods (MAMs)
June 1, 2017
Indianapolis, IN, USA
Genedata, a leading provider of advanced software solutions for R&D, today announced the global release of Genedata Expressionist 11.0, the latest version of its market-leading enterprise software solution for the characterization of biopharmaceutical molecules based on mass spectrometry (MS). Genedata is showcasing Genedata Expressionist 11.0 at booth #510 at the 65th American Society for Mass Spectrometry (ASMS) Conference in Indianapolis, IN, from June 4–8. Seven posters highlighting the application of Genedata Expressionist to MS data will be presented at the conference and Joe Shambaugh from Genedata will also present a talk entitled Automated Data Processing for Quality Monitoring of Biotherapeutics by Multi-attribute Methods (MAMs).
Genedata Expressionist is an innovative, highly scalable, instrument vendor-independent software platform that harmonizes and automates complex data analysis workflows in biotherapeutics R&D. Designed for GxP environments, the end-to-end enterprise software platform integrates state-of-the-art algorithms for MS data analytics and intuitive visualizations for quick decision-making, enabling scientists to obtain reproducible, high-quality results with significant time and cost savings. In particular, Genedata Expressionist has been developed to support the application of multi-attribute methods (MAMs) for the identification and monitoring of critical quality attributes (CQAs) of biotherapeutics.
Genedata Expressionist 11.0 marks a new milestone in accelerating biotherapeutics characterization processes at best quality. The latest software release introduces an all-new project management extension that mitigates the communication challenges faced by teams collaborating on many projects across labs. The project management extension facilitates communication of data and results across projects, helping to eliminate core R&D bottlenecks—pertinent data, results, and project-related information are quickly and intuitively accessible through a new web-based gateway dedicated to each user, facilitating collaboration within organizations and eliminating the need for any other communication channel. The extension was developed with particular focus on MAM implementations, which require the identification and quantification of quality attributes in the early stages of a molecule’s life cycle and ultimately the monitoring of CQAs in the late development and manufacturing stages. The new project management extension in Genedata Expressionist 11.0 now enables consolidation and dissemination of product knowledge across different functions, key for the efficient implementation of MAMs.
Additionally, Genedata Expressionist 11.0 introduces an open plugin infrastructure to enable customers to add their own proprietary algorithms, while utilizing the automation and reporting framework that Genedata Expressionist provides. For example, users can now seamlessly integrate Python, R, Perl or Bash scripts for data processing, analysis and reporting via an intuitive interface.
Genedata Expressionist is renowned for providing an unbiased view of the data, for detecting the unexpected through state-of-the-art pattern recognition algorithms, and for accelerating critical decision-making through intuitive visualizations. Release 11.0 introduces brand new visualizers that change the way scientists can look at MS data. For example, the new interactive peptide mapping viewer enables intuitive visualization of sequence coverage, quick differentiation between identification types, mapping of identified PTMs and glycans, and visualization of peptide abundance. Also, improvements for intact mass analysis, released glycan analysis and host cell protein analysis increase speed of characterization workflows and thus help to maximize clients’ return on their investment in R&D.
“Genedata Expressionist is a major component of our biopharma platform strategy,” commented Dr. Othmar Pfannes, CEO of Genedata. “With the latest release, we again show our commitment to provide our rapidly growing customer base with a state-of-the art data analysis platform for the characterization of biopharmaceuticals. Genedata also plans to extend its partnering and collaboration program with third-party software providers. To start with, Genedata Expressionist 11.0 now integrates with the de-novo search engine PEAKS for automated routine tasks.”
From biologics discovery and development to bioprocess development and manufacturing of biologics and biosimilars, Genedata will continue to invest significant resources to address clients’ challenges and help them to bring innovative biotherapeutics of the highest quality to the market as quickly as possible, with lowest costs.
Genedata will attend the 65th American Society for Mass Spectrometry (ASMS) Conference on Mass Spectrometry and Allied Topics in Indianapolis, IN, participating in the scientific program with posters and an oral presentation, and in the exhibition at booth #510. Conference participants are invited to the Genedata hospitality suite #108 in the JW Marriott Indianapolis Hotel.
Genedata transforms data into intelligence with innovative software solutions that incorporate extensive biopharma R&D domain knowledge. Multinational biopharmaceutical organizations and cutting-edge biotechs around the globe rely on Genedata to digitalize and automate data-rich and complex R&D processes. From early discovery all the way to the clinic, Genedata solutions help maximize the ROI in R&D expenditure. Founded in 1997, Genedata is headquartered in Basel, Switzerland with additional offices in Boston, London, Munich, San Francisco, Singapore, and Tokyo.
LinkedIn | Twitter | YouTube
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
All product and service names mentioned are the trademarks of their respective companies.